STAT3 and cancer: PLK1 has emerged as a key regulator of multiple transcription factors, including STAT3, c-Myc, FOXM1, and β-catenin, positioning it as a promising combinatorial therapeutic target for disrupting oncogenic signaling networks in cancer [24, 27, 47].